The marketing around weight loss drugs tends to cherry-pick the most dramatic results. So let's look at what the actual clinical trials found — specifically SURMOUNT-1, the largest tirzepatide weight loss trial.

SURMOUNT-1: The Numbers by Dose

SURMOUNT-1 enrolled 2,539 adults with obesity or overweight (with at least one related condition) who did NOT have diabetes. Participants were randomized to tirzepatide 5mg, 10mg, or 15mg versus placebo for 72 weeks.

Average body weight loss at 72 weeks:
- 5mg dose: 15.0% (about 34 pounds for a 225-pound person)
- 10mg dose: 19.5% (about 44 pounds)
- 15mg dose: 20.9% (about 47 pounds)
- Placebo: 3.1%

Percentage of patients losing 20%+ body weight:
- 5mg: 32%
- 10mg: 46%
- 15mg: 57%
- Placebo: 1.3%

These are averages. Some people lost more, some less. But even the lowest dose beat anything available before these drugs existed.

The Week-by-Week Reality

Here's roughly what the data and clinical experience suggest you can expect:

Weeks 1-4 (2.5mg starting dose)

You're on the lowest dose. Most people notice reduced appetite within the first 1-2 weeks. Weight loss is typically 2-5 pounds, some of which is water. The main thing you'll notice is that "food noise" — that constant background hum of thinking about food — starts to quiet down.

Weeks 5-8 (5mg)

After the first dose increase, appetite suppression becomes more noticeable. Weight loss accelerates to roughly 1-2 pounds per week. You might find yourself forgetting to eat, which feels bizarre if you've spent your life thinking about food constantly.

Weeks 9-20 (titrating through 7.5mg to 10mg)

This is when most people hit their stride. Average weight loss is consistently 1-2 pounds per week. Clothes start fitting differently. People start commenting.

Weeks 20-40 (10mg-15mg)

Steady, predictable loss. The rate may slow slightly as you have less weight to lose, but it's consistent. Many people describe feeling like a different person around food.

Weeks 40-72 (maintenance dose)

Weight loss continues but more gradually. You're approaching your plateau, which is where your body finds its new equilibrium on the medication. Most of the total loss happens by this point.

What "Food Noise" Actually Means

This term has become common, but it's worth explaining properly. Food noise refers to the persistent, intrusive thoughts about food that many people with obesity experience. When is the next meal? What should I eat? I shouldn't eat that, but I want it. I just ate but I'm still thinking about food.

It's not about willpower. It's a neurological pattern driven by hormone signaling — specifically how GLP-1 and GIP receptors in the brain regulate appetite and reward.

Tirzepatide acts on both these receptor systems. Most patients report that food noise diminishes within the first 2-4 weeks. For many, it's the most life-changing aspect of the medication — more than the weight loss itself.

Dose Titration: Why You Start Low

Everyone starts at 2.5mg, regardless of their weight or goals. This isn't a therapeutic dose — it's a tolerability dose. The purpose is to let your GI system adjust.

Standard titration schedule:
- Weeks 1-4: 2.5mg
- Weeks 5-8: 5mg
- Weeks 9-12: 7.5mg
- Weeks 13-16: 10mg
- Weeks 17+: 12.5mg or 15mg (if needed)

Your provider may adjust this. Some people stay at 10mg because they're getting good results without needing a higher dose. Others titrate faster or slower based on tolerability.

Rushing titration is the fastest way to get miserable GI side effects. The slow climb is intentional.

What Happens When You Stop

This is the part nobody loves hearing. The SURMOUNT-4 trial specifically studied this question. Patients who discontinued tirzepatide after 36 weeks regained about two-thirds of their lost weight over the following 52 weeks.

That's not unique to tirzepatide. It's true of semaglutide, anti-hypertensives, statins — most medications for chronic conditions work while you take them. Obesity is a chronic metabolic condition, and these drugs treat it chronically.

Some people eventually taper to lower doses. Some use cyclical dosing. The research on long-term protocols is still developing. But the expectation should be that this is an ongoing treatment, not a short-term fix.